Latest news with #Laflamme
Vancouver Sun
24-06-2025
- Science
- Vancouver Sun
Raymond Laflamme, Canadian pioneer in quantum computing, has died
Raymond Laflamme, a Canadian pioneer in the field of quantum information processing who once worked with Stephen Hawking, has died after a lengthy bout with cancer. The University of Waterloo announced his death in a press release this week. He died June 19 on what would have been his 65th birthday. Born in Québec City, the third of five siblings, Laflamme studied physics as an undergraduate at the Université Laval before moving to England to continue his education there. At Cambridge University, he earned his PhD under the supervision of Stephen Hawking, at one point convincing the eminent scientist (over the course of six months' spirited discussion) that Hawking was wrong in his belief that time would run backwards during the contraction of the universe. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. Hawking gave credit to Laflamme for this contribution in his best-selling book A Brief History of Time. When Laflamme left Cambridge a few years later, Hawking personalized his copy of the book with a note reading: 'To Raymond, who showed me that the arrow of time is not a boomerang. Thank you for all your help. Stephen.' Years later, Hawking visited Laflamme at his workplace in Waterloo, Ont., during which his former student gave him a tour of labs, introduced him to faculty, students and staff — and presented him with a boomerang, engraved with the words: 'Come back soon!' After Cambridge, Laflamme worked for a number of years at the Los Alamos National Laboratory in New Mexico, where his interests shifted from cosmology to quantum computing. In 2001, he returned to Canada and joined the department of physics and astronomy at the University of Waterloo and the university's newly created Perimeter Institute for Theoretical Physics. There, he became founding director of the Institute for Quantum Computing, a position he held for 15 years. 'Through his leadership, IQC became a world-class research hub, positioning Canada at the forefront of the quantum revolution,' the university said in its release. 'In his scientific research, Laflamme pioneered theoretical and experimental approaches to quantum information processing and quantum error correction.' It added: 'Laflamme and colleagues developed an innovative approach to quantum information processing using linear optics, the results of which became one of the most referenced works in quantum computing.' On the occasion of the 15th anniversary of the IQC, Hawking was among the luminaries to pay tribute to Laflamme's achievements. 'The incredible growth and success of IQC are a testament to professor Raymond Laflamme's leadership,' he said. 'Under Raymond's guidance, IQC has established Waterloo and Canada as the world-leading hub for research in quantum technologies and their applications.' Laflamme's many accolades included being named an Officer of the Order of Canada, the Canadian Association of Physicists CAP-CRM Prize in Theoretical and Mathematical Physics, and a Queen Elizabeth II Diamond Jubilee Medal. He was a Fellow of the Royal Society of Canada, a Fellow of the American Physical Society, and a Fellow of the American Association for the Advancement of Science. He held the inaugural Mike and Ophelia Lazaridis 'John von Neumann' Chair in Quantum Information. He coauthored two textbooks on quantum computing: Building Quantum Computers: A Practical Introduction and An Introduction to Quantum Computing. In 2020, he and his wife, Janice Gregson, established the Raymond Laflamme and Janice Gregson Graduate Scholarship for Women in Quantum Information Science, awarded annually to recognize top women entering Waterloo's quantum graduate programs. 'Throughout his career, he found ways to bring people together,' the university said in its release. 'This was accomplished on an international scale by leading networks and organizing conferences, and within the local community through pick-up hockey games and sharing his insights generously with students and colleagues.' The university noted that, when he was diagnosed with lung cancer, Laflamme started a project with researchers at Grand River Hospital in Kitchener, Ont., to investigate quantum technologies for cancer research and treatment. Laflamme is survived by Gregson and his children, Patrick and Jocelyne. Cremation has taken place, and a celebration of life will be announced at a later date. In lieu of flowers, the family says donations may be made to Lung Cancer Canada, Princess Margaret Foundation or the Waterloo Regional Health Network Foundation – Cancer Centre. The family is also working towards setting up a scholarship fund in Laflamme's memory. An obituary at Erb & Good Family Funeral Home noted Laflamme's love for the outdoors. 'In recent years, he and Janice went on bike tours through France, and Ray embarked on two canoe trips to the Arctic — one with Patrick, one with Jocelyne,' it said, adding: 'He had a knack for turning any project into something special, from building a log cabin sauna by hand to restoring his cherished 1979 VW bus.' The obituary also includes a tribute wall. One person posted: 'Although I only met Ray Laflamme once, I'll never forget his patience in explaining, in lay terms, quantum computing to me.' They added: 'I first learned about his lung cancer diagnosis in an interview with him in the (Waterloo Region) Record. He was speaking out about the importance of early screening for a cancer that is the leading cause of death. The courage he displayed by going public in that article only increased my respect for him. My condolences to his family.' Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our newsletters here .
Ottawa Citizen
24-06-2025
- Science
- Ottawa Citizen
Raymond Laflamme, Canadian pioneer in quantum computing, has died
Article content Raymond Laflamme, a Canadian pioneer in the field of quantum information processing who once worked with Stephen Hawking, has died after a lengthy bout with cancer. Article content The University of Waterloo announced his death in a press release this week. He died June 19 on what would have been his 65th birthday. Article content Article content Born in Québec City, the third of five siblings, Laflamme studied physics as an undergraduate at the Université Laval before moving to England to continue his education there. Article content Article content At Cambridge University, he earned his PhD under the supervision of Stephen Hawking, at one point convincing the eminent scientist (over the course of six months' spirited discussion) that Hawking was wrong in his belief that time would run backwards during the contraction of the universe. Article content Article content Hawking gave credit to Laflamme for this contribution in his best-selling book A Brief History of Time. When Laflamme left Cambridge a few years later, Hawking personalized his copy of the book with a note reading: 'To Raymond, who showed me that the arrow of time is not a boomerang. Thank you for all your help. Stephen.' Article content Article content Article content After Cambridge, Laflamme worked for a number of years at the Los Alamos National Laboratory in New Mexico, where his interests shifted from cosmology to quantum computing. Article content Article content In 2001, he returned to Canada and joined the department of physics and astronomy at the University of Waterloo and the university's newly created Perimeter Institute for Theoretical Physics. There, he became founding director of the Institute for Quantum Computing, a position he held for 15 years. Article content 'Through his leadership, IQC became a world-class research hub, positioning Canada at the forefront of the quantum revolution,' the university said in its release. 'In his scientific research, Laflamme pioneered theoretical and experimental approaches to quantum information processing and quantum error correction.' Article content It added: 'Laflamme and colleagues developed an innovative approach to quantum information processing using linear optics, the results of which became one of the most referenced works in quantum computing.'
Calgary Herald
24-06-2025
- Science
- Calgary Herald
Raymond Laflamme, Canadian pioneer in quantum computing, has died
Raymond Laflamme, a Canadian pioneer in the field of quantum information processing who once worked with Stephen Hawking, has died after a lengthy bout with cancer. Article content The University of Waterloo announced his death in a press release this week. He died June 19 on what would have been his 65th birthday. Article content Article content Born in Québec City, the third of five siblings, Laflamme studied physics as an undergraduate at the Université Laval before moving to England to continue his education there. Article content Article content At Cambridge University, he earned his PhD under the supervision of Stephen Hawking, at one point convincing the eminent scientist (over the course of six months' spirited discussion) that Hawking was wrong in his belief that time would run backwards during the contraction of the universe. Article content Article content Article content Article content After Cambridge, Laflamme worked for a number of years at the Los Alamos National Laboratory in New Mexico, where his interests shifted from cosmology to quantum computing. Article content Article content In 2001, he returned to Canada and joined the department of physics and astronomy at the University of Waterloo and the university's newly created Perimeter Institute for Theoretical Physics. There, he became founding director of the Institute for Quantum Computing, a position he held for 15 years. Article content 'Through his leadership, IQC became a world-class research hub, positioning Canada at the forefront of the quantum revolution,' the university said in its release. 'In his scientific research, Laflamme pioneered theoretical and experimental approaches to quantum information processing and quantum error correction.' Article content It added: 'Laflamme and colleagues developed an innovative approach to quantum information processing using linear optics, the results of which became one of the most referenced works in quantum computing.'
Indianapolis Star
16-06-2025
- Health
- Indianapolis Star
Clinique Laflamme Wins the 2025 Consumer Choice Award
MONTRÉAL, QC / ACCESS Newswire The Consumer Choice Award (CCA) is proud to name Clinique Laflamme as the top medical aesthetic clinic in the Greater Montreal area. This prestigious recognition highlights the excellence of an establishment at the intersection of science, cutting-edge technology, and the art of personalized beauty. Since its founding in 2010, Clinique Laflamme has established itself as a leading authority in medical aesthetics in Quebec. Its mission is clear: to place medicine at the service of natural, lasting beauty, while respecting overall well-being, through a personalized approach and the integration of next-generation technologies. At the heart of this vision is Dr. Nathalie Laflamme, a physician recognized in aesthetic medicine by the Collège des médecins du Québec. Certified by the European College of Aesthetic Medicine & Surgery (ECAMS), she is a leading expert in advanced aesthetic injectables and tissue biostimulation, offering holistic and harmonious rejuvenation with natural results and customized care. Creator of the exclusive Lift Laflamme© protocol, she embodies a new generation of aesthetic physicians combining technical mastery with artistic vision. Driven by a constant desire to refine her practice, Dr. Laflamme has expanded her expertise through advanced training in Europe, the United States, and Canada. This ongoing commitment to education allows her to remain at the forefront of the most effective, innovative, and safest medical advancements in the field. Clinique Laflamme offers a full range of high-end medical-aesthetic treatments, including: Next generation injectables: neuromodulators and tailored fillers to smooth wrinkles, sculpt volume, and enhance features with finesse. Laser and light-based technologies: for pigmentation correction, skin tightening, collagen stimulation, and precision hair removal. Non-invasive body contouring: advanced technology solutions designed to sculpt the body without surgery or downtime. Medical-grade skincare: personalized treatments that promote luminous, even, and resilient skin. Tissue biostimulation: a revolutionary breakthrough that reactivates the skin's natural regenerative power, from face to body, for a tightening effect and deep revitalization – all without invasive procedures. 'This award reflects our commitment to delivering ethical, science-based, and personalized aesthetic care. We believe in an evolving beauty – one that is supported by medical intelligence, technological precision, and a deep understanding of our patients,' says Dr. Laflamme. 'We are deeply grateful to our patients for their continued trust. It is an honour we carry with pride and responsibility.' Guided by a culture of excellence, Clinique Laflamme stands as a leader in modern aesthetic medicine. Visionary, refined, and deeply human, it remains the destination of choice for those seeking personalized care, elegant results, and a safe, cutting-edge approach to beauty and well-being. To learn more about Clinique Laflamme, CLICK HERE or visit About Consumer Choice Award: Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit to learn more. Contact Information: Sumi Saleh Communications Manager ssaleh@ SOURCE: Consumer Choice Award View the original press release on ACCESS Newswire
Cision Canada
29-05-2025
- Business
- Cision Canada
LSL PHARMA GROUP REPORTS RECORD REVENUES AND FIRST QUARTER 2025 RESULTS
Filed 6 new Eye-care products with Health Canada 5 th consecutive positive EBITDA performance BOUCHERVILLE, QC, May 29, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (the " Corporation" or " LSL Pharma"), a Canadian integrated pharmaceutical company, today reported record quarterly revenues and its financial results for the first quarter of its 2025 fiscal year, ended March 31, 2025, with comparable results for the prior year ("Q1-25" and "Q1-24"). All amounts are presented in thousands of Canadian dollars. Q1-25 vs Q1-24 Record quarterly revenues of $6.6 million compared to $4.2 million, up 59%; CMO revenues of $5.7 million compared to $1.4 million, up 300%; Eye-care revenues of $0.9 million compared to $2.7 million, down 68%; Operating Profit was $0.4 million, up 150%; Net loss of $0.2 million, down 44%; Adjusted EBITDA of $0.9 million compared to $0.5 million, up 79%. Corporate Development Completed the purchase of a new state-of-the-art manufacturing line to increase production capacity at the Steri-Med Pharma plant and facilitate the development of new Eye-care products; Appointed Mr. Louis Laflamme to its board of directors. Mr. Laflamme was President, CEO and director of OpSens Inc. (TSX: OPS) from January 2013 to March 2024 prior to its acquisition for $345 million. Subsequent to the end of Q1-25 Entered into two strategic agreements to expand the Eye-Care pipeline with up to ten (10) new eye-drop products; Completed the regulatory filing of six (6) new Eye-care products with Health Canada to expand its Eye-care product portfolio; Subsequent to the end of the quarter, the Corporation was notified of a court ruling against LSL Laboratory Inc. regarding a dispute over certain costs related to the building and relocation of its plant in 2022. The amount of the ruling amounts to $0.3 million plus interest. The Corporation intends to vigorously contest this ruling and is currently assessing its rights to appeal the court decision. Should the Corporation be required to pay any amount under this claim, such amount would be capitalized as leasehold improvement representing an addition to our long-term assets. "Q1-25 was another great quarter for LSL Pharma. The Dermolab Pharma and Virage Santé acquisitions have been fully integrated into our CMO platform and providing material impact on our results", mentioned Francois Roberge, President and CEO of LSL Pharma. "Our Eye-care operations, a strategic priority, have already met several key milestones since the start of the year with 1) significant progress for securing FDA approval to manufacture Avaclyr and other products for the US market, 2) filing of 6 new eye-care products with Health Canada, and 3) initiated the installation of our new $1.7M state-of-the-art ointment filing line", added M. Roberge. "Both Virage Santé and Dermolab contributed a full quarter in Q1-25 and helped LSL Pharma reach record quarterly revenues, including a significant 4-fold increase of our CMO revenue. We achieved a 59% increase of our total revenues despite a 68% decline for our Eye-care segment which benefited from non-recurrent revenues in Q1-24. Q1-25 results provide a solid base for the next phase of our development to drive continuous financial performance improvement in the coming quarters" said Luc Mainville, Executive Vice-president and CFO of LSL Pharma. First Quarter Financial Results – Three-Month Period Ended March 31, 2025 Change Q1-25 Q1-24 $ % Revenues CMO 5,748 1,438 4,310 300 % Eye-Care 877 2,725 (1,848) -68 % Total Revenues 6,625 4,163 2,462 59 % Gross profit (loss) 2,106 1,146 960 84 % Adjusted Gross Profit 2,542 1,480 1,062 72 % SG&A (1,659) (967) (692) 72 % Operating Profit 447 179 268 150 % Share-based Compensation (14) - (14) 100 % Financial Expenses (588) (459) (129) 28 % Net loss (155) (280) 125 -45 % EBITDA 904 513 391 76 % Adjusted EBITDA 918 513 405 79 % ADJUSTED GROSS PROFIT RECONCILIATION Change Q1-25 Q1-24 $ % Revenues 6,625 4,163 2,462 59 % Gross profit 2,106 1,146 960 84 % Gross profit as % of revenues 31,8 % 27,5 % 4,3 % (+/-) Adjustments Depreciation and amortization 436 334 102 31 % Adjusted Gross Profit 2,542 1,480 1,062 72 % Adjusted Gross Profit as % of revenues 38,4 % 35,6 % 2,8 % ADJUSTED EBITDA RECONCILIATION Change Q1-25 Q1-24 $ % Net loss (155) (280) 125 -41 % Finance expense, net 588 459 129 27 % Depreciation and amortization 471 334 137 44 % EBITDA 904 513 391 78 % % of revenues 13,6 % 12,3 % 1,3 % (+/-) Adjustments Stock-based compensation 14 - 14 100 % Adjusted EBITDA 918 513 405 79 % % of revenues 13,9 % 12,3 % 1,5 % Adjusted Gross Margin, EBITDA, and Adjusted EBITDA are non-IFRS measures and do not have any standardized meaning under IFRS. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to Non-IFRS Financial measures for additional details. Revenues - The Corporation delivered record quarterly revenues in Q1-25, at $6.6 million, up 59% compared to Q1-24. Due to the addition of revenues from Dermolab and Virage Santé, both acquired last year, CMO revenues quadrupled at $5.7 million in Q1-25 compared to $1.4 million for Q1-24, a 300% increase. Also, CMO revenues benefited from the growth in revenues at LSL Laboratory which is now leveraging the capital investments made over the last 2 years for expanding its service offering and capacity. Revenues from the Eye-care division were down 68% during Q1-25 compared to Q1-24. Last year, Q1-24 revenues benefited from important non-recurrent sale of products to the US under an FDA exemption due to a local shortage of Erythromycin (the "US Shortage"). Such sales ended in Q1-24. Adjusted Gross Profit for Q1-25 after eliminating the impact of depreciation and amortization, stood at $2.5 million, a 72% increase over Q1-24. Adjusted Gross Profit benefited from the contribution of Dermolab and Virage Santé for the full quarter. The increased production at all 4 sites also contributed to improve gross profit as the plants were able to increase production compared to last year. SG&A expenses for Q1-25 were $1.7 million compared to $1.0 million in Q1-24, a 72% increase, mainly due to the addition of Dermolab and VSI. The increase in SG&A expenses was in line with the increase in revenues. We expect SG&A expenses to decrease as a % of total revenues going forward. Operating Profit - LSL Pharma generated operating profits in Q1-25 at $0.4 million compared to a $0.2 million last year. The $0.3 million, or 150% improvement was due to the strong increase in revenues, and increased production for all 4 sites. Financial Expenses for Q1-25 were 28% higher than Q1-24. Despite the conversion and repayment of several debt/loans during the year, financial expenses for Q1-25 were impacted by the increased expenses on lease facilities as the LSL Laboratory, addition of the Dermolab lease starting December 2024. Several initiatives were taken during last year to reduce the cost of carrying our various loans and debts. These initiatives should help reduce our cost of capital for the upcoming year. Net loss - For the Q1-25 period, the Corporation reduced its net loss by 45% compared to Q1-24 at $0.2 million. The Quarter-over-Quarter performance was due to an increase in gross profit between the periods derived from the strong increase in revenues which more than offset the increase in SG&A and financial expenses. EBITDA for Q1-25, after eliminating the impact of financial expenses, depreciation and amortization was $0.9 million compared to $0.5 million for Q1-24, representing a strong 76% increase. Adjusted EBITDA - After eliminating share-based compensation, and other non-recurrent items, Adjusted EBITDA for Q1-25 was a $0.9 million profit compared to $0.5 million for Q1-24 representing a 79% improvement. Selected Balance Sheet items Change As at the end of the period Q1-25 YE-24 $ % Current assets 17,693 15,376 2,317 15 % Fixed assets 22,941 22,939 2 0 % Intangible assets 13,430 13,272 158 1 % Total assets 55,987 53,510 2,477 5 % Current liabilities 11,721 9,652 2,069 21 % Long-term notes payable 3,629 3,621 8 0 % Long-term debt excluding lease liabilities 9,604 8,903 701 8 % Total Liabilities 31,236 28,618 2 618 9 % Shareholders' equity 24,751 24,892 (141) -1 % Current assets increased by 15% at the end of Q1-25 compared to YE-24. The $2.3 million increase comes mainly from a $2.6 million increase in inventory, partly offset by a decrease in cash, accounts receivable and prepaids. Our inventory level at the end of Q1-25 reflects the increase in operating and commercial activities during quarter compared to the last portion of FY-24. Total Assets increased by 5% at the end of Q1-25 compared to YE-24, a $2.5 million increase in line with the increase in short-term assets plus a nominal increase in intangible assets as the Corporation kept investing in its Eye-care product pipeline. Current liabilities have increased by $2.1 million in Q1-25 with accounts payable increasing by $1.2 million, the addition of a $0.75 million note and $0.6 million of other liabilities, partly offset by a $0.3 million decrease in the short-term portion of LTD. The increase in short-term liabilities was in line with the increase in short-term assets. Long-term notes payable and long-term debt excluding lease liabilities increased by $0.7 million between YE-24 and the end of Q1-25 reflecting further advances from Finacces Capital, and extension of some equipment loans. Total liabilities increased by 9% at the end of Q1-25 compared to YE-24. The increase in total liabilities resulted mainly from the increase in short-term liabilities. Shareholders Equity decreased slightly in Q1-25, reflecting the nominal loss for the period. Financial Statements and MD&A LSL Pharma Group's unaudited financial statements and Management's Discussion and Analysis for Q1-25 are available on SEDAR+ at and on the Corporation's website. Caution regarding forward-looking statements This press release may contain forward-looking statements as defined under applicable Canadian securities legislation. Forward looking statements include estimates and statements that describe the Corporation's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition, belief, estimate or opinion, or result to occur. Forward-looking statements may be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "believe", "aim", "plan" "continue" or similar expressions. Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Corporation's ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, those identified in the Corporation's filings with Canadian securities regulatory authorities, such as legislative or regulatory developments, increased competition, technological change and general economic conditions. All forward-looking statements made herein should be read in conjunction with such documents. Readers are cautioned not to place undue reliance on forward-looking statements. No assurance can be given that any of the events referred to in the forward-looking statements will transpire, and if any of them do, the actual results, performance or achievements of the Corporation may differ materially from those expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. The Corporation does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. About LSL Pharma Group Inc. LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing, and marketing of high-quality sterile ophthalmic pharmaceuticals, as well as cosmetic, pharmaceutical, and natural health products in solid, semi-solid and liquid dosage forms. For further information, please visit the Corporation's website Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE Groupe LSL PHARMA INC.
